Sermonix Pharmaceuticals, Inc.

Overview

• HeadquartersDE¹
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Sermonix Pharmaceuticals, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorAnthony Wild named Nov 23, 2021²
• Executive OfficerBarry Komm named Nov 23, 2021²
• Executive Officer, Director, PromoterDavid Portman named Nov 23, 2021²
• Executive OfficerElizabeth Attias named Nov 23, 2021²
• Executive Officer, PromoterMiriam Portman named Nov 23, 2021²
• Executive OfficerPaul Plourde named Nov 23, 2021²
• Executive OfficerSimon Jenkins named Nov 23, 2021²
• DirectorElizabeth Garner named Nov 23, 2021²
• DirectorMichael Friedman named Nov 23, 2021²
• DirectorRichard De Schutter named Nov 23, 2021²
• DirectorThomas Pfisterer named Nov 23, 2021²

Filings

1 filings to the SEC since October 2021: 1 private raises. The latest 1:

1. Nov 23, 2021D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

Sermonix Pharmaceuticals, Inc. has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

• LeonaBio, Inc.SCHEDULE 13D Aug 31, 2026³

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Nov 12, 2021Raised $40.2 million in a private offering of equity² Form D: 9 investors so far Form D